Clinical Trial Update: A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer [NA]

View source ↗

Summary

Phase II single-arm study evaluating camrelizumab in combination with radiochemotherapy as neoadjuvant therapy for early-stage triple-negative breast cancer; no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: TNBC | NA | Status: NOT_YET_RECRUITING